RE-VANA
Developing photocrosslinked technologies for delivery of a wide range of therapeutics that may dramatically extend the time between intravitreal.
Launch date
Employees
Market cap
-
Enterprise valuation
€43—65m (Dealroom.co estimates Dec 2022.)
Company register number NI638333
Belfast Northern Ireland (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
£1.2m | Seed | ||
£190k | Grant | ||
$3.3m | Seed | ||
£170k | Grant | ||
* | $11.9m | Series A | |
| Total Funding | €15.6m | ||
Related Content
Recent News about RE-VANA
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.